Blood:终于鉴定出与人疾病相关的iNKT表型!

2020-01-23 QQY MedSci原创

中心点:鉴定出效应功能具有明显区别的临床相关人iNKT细胞表型。本研究阐明了显性iNKTcell在GVHD患者和异源造血干细胞移植(alloc -HSCT)和自身免疫系统重建后的健康患者中的异质性。摘要:人恒定型自然杀伤T细胞(iNKTs)是一种罕见的能识别CD1d上的糖脂的先天淋巴细胞群。在小鼠上的研究显示这些细胞具有异质性,可行使完全不同的功能,iNKT亚细胞的组成可影响疾病预后。但迄今为止,

中心点:

鉴定出效应功能具有明显区别的临床相关人iNKT细胞表型。

本研究阐明了显性iNKTcell在GVHD患者和异源造血干细胞移植(alloc -HSCT)和自身免疫系统重建后的健康患者中的异质性。

摘要:

人恒定型自然杀伤T细胞(iNKTs)是一种罕见的能识别CD1d上的糖脂的先天淋巴细胞群。在小鼠上的研究显示这些细胞具有异质性,可行使完全不同的功能,iNKT亚细胞的组成可影响疾病预后。

但迄今为止,尚未发现人iNKT细胞的异质性如何与疾病相关。

为了弥补这一空白,Erkers等人采用高维、数据驱动的方法设计了一个框架,用来解析人iNKT的异质性。

本研究数据揭示了新的与既往描述的iNKT表型具有不同功能的新iNKT亚型。研究人员对两种特别感兴趣的表型进行深入分析:1)一种具有Th1功能,iNKT激活时数量增加,以HLA-II+CD161-表达为特征的;2)另一种的细胞毒性功能增强,以CD4-CD94+表达为特征。这两种表型分别与异源造血干细胞移植后的急性移植物抗宿主病和新发的1型糖尿病有关。

本研究确定了与人疾病相关的iNKT表型,这可能有助于开发针对iNKT的生物标志物或治疗方法。

原始出处:

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1751739, encodeId=ee041e51739a9, content=<a href='/topic/show?id=ba8612842b3' target=_blank style='color:#2F92EE;'>#NKT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12842, encryptionId=ba8612842b3, topicName=NKT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74e936405699, createdName=xuruicheng, createdTime=Thu May 21 01:43:00 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1989640, encodeId=d0ee198964089, content=<a href='/topic/show?id=13c698665d' target=_blank style='color:#2F92EE;'>#iNKT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9866, encryptionId=13c698665d, topicName=iNKT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Tue Apr 07 07:43:00 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535253, encodeId=e9261535253a5, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Fri Jan 24 16:43:00 CST 2020, time=2020-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378429, encodeId=f0363e84296d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Thu Jan 23 14:10:15 CST 2020, time=2020-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378425, encodeId=31c33e8425dd, content=谢谢了学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Thu Jan 23 07:36:41 CST 2020, time=2020-01-23, status=1, ipAttribution=)]
    2020-05-21 xuruicheng
  2. [GetPortalCommentsPageByObjectIdResponse(id=1751739, encodeId=ee041e51739a9, content=<a href='/topic/show?id=ba8612842b3' target=_blank style='color:#2F92EE;'>#NKT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12842, encryptionId=ba8612842b3, topicName=NKT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74e936405699, createdName=xuruicheng, createdTime=Thu May 21 01:43:00 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1989640, encodeId=d0ee198964089, content=<a href='/topic/show?id=13c698665d' target=_blank style='color:#2F92EE;'>#iNKT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9866, encryptionId=13c698665d, topicName=iNKT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Tue Apr 07 07:43:00 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535253, encodeId=e9261535253a5, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Fri Jan 24 16:43:00 CST 2020, time=2020-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378429, encodeId=f0363e84296d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Thu Jan 23 14:10:15 CST 2020, time=2020-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378425, encodeId=31c33e8425dd, content=谢谢了学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Thu Jan 23 07:36:41 CST 2020, time=2020-01-23, status=1, ipAttribution=)]
    2020-04-07 dingxiaobo
  3. [GetPortalCommentsPageByObjectIdResponse(id=1751739, encodeId=ee041e51739a9, content=<a href='/topic/show?id=ba8612842b3' target=_blank style='color:#2F92EE;'>#NKT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12842, encryptionId=ba8612842b3, topicName=NKT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74e936405699, createdName=xuruicheng, createdTime=Thu May 21 01:43:00 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1989640, encodeId=d0ee198964089, content=<a href='/topic/show?id=13c698665d' target=_blank style='color:#2F92EE;'>#iNKT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9866, encryptionId=13c698665d, topicName=iNKT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Tue Apr 07 07:43:00 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535253, encodeId=e9261535253a5, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Fri Jan 24 16:43:00 CST 2020, time=2020-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378429, encodeId=f0363e84296d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Thu Jan 23 14:10:15 CST 2020, time=2020-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378425, encodeId=31c33e8425dd, content=谢谢了学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Thu Jan 23 07:36:41 CST 2020, time=2020-01-23, status=1, ipAttribution=)]
    2020-01-24 tastas
  4. [GetPortalCommentsPageByObjectIdResponse(id=1751739, encodeId=ee041e51739a9, content=<a href='/topic/show?id=ba8612842b3' target=_blank style='color:#2F92EE;'>#NKT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12842, encryptionId=ba8612842b3, topicName=NKT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74e936405699, createdName=xuruicheng, createdTime=Thu May 21 01:43:00 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1989640, encodeId=d0ee198964089, content=<a href='/topic/show?id=13c698665d' target=_blank style='color:#2F92EE;'>#iNKT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9866, encryptionId=13c698665d, topicName=iNKT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Tue Apr 07 07:43:00 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535253, encodeId=e9261535253a5, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Fri Jan 24 16:43:00 CST 2020, time=2020-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378429, encodeId=f0363e84296d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Thu Jan 23 14:10:15 CST 2020, time=2020-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378425, encodeId=31c33e8425dd, content=谢谢了学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Thu Jan 23 07:36:41 CST 2020, time=2020-01-23, status=1, ipAttribution=)]
    2020-01-23 天地飞扬

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1751739, encodeId=ee041e51739a9, content=<a href='/topic/show?id=ba8612842b3' target=_blank style='color:#2F92EE;'>#NKT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12842, encryptionId=ba8612842b3, topicName=NKT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74e936405699, createdName=xuruicheng, createdTime=Thu May 21 01:43:00 CST 2020, time=2020-05-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1989640, encodeId=d0ee198964089, content=<a href='/topic/show?id=13c698665d' target=_blank style='color:#2F92EE;'>#iNKT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9866, encryptionId=13c698665d, topicName=iNKT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Tue Apr 07 07:43:00 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535253, encodeId=e9261535253a5, content=<a href='/topic/show?id=099f9020145' target=_blank style='color:#2F92EE;'>#表型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90201, encryptionId=099f9020145, topicName=表型)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9b6412593156, createdName=tastas, createdTime=Fri Jan 24 16:43:00 CST 2020, time=2020-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378429, encodeId=f0363e84296d, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Thu Jan 23 14:10:15 CST 2020, time=2020-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378425, encodeId=31c33e8425dd, content=谢谢了学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Thu Jan 23 07:36:41 CST 2020, time=2020-01-23, status=1, ipAttribution=)]
    2020-01-23 txqjm

    谢谢了学习了

    0

相关资讯

Cell Chem Biol:科学家开发出新型化合物 能有效激活特殊抗癌T细胞的功能

不变的自然杀伤T细胞(iNKT)是机体免疫系统非常强大的武器,其能帮助抵御包括癌症、多发性硬化症及狼疮等多种疾病,如果能找到一种利用iNKT细胞功能的方法,那么研究人员未来或有望开发出更多新型的癌症疗法或疾病疫苗了。目前多种化合物都能有效刺激小鼠机体中的iNKT细胞,然而激活人类iNKT细胞的能力却非常有限。